Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Dell Technologies Inc (DELL) Price & Performance

Citius Pharmaceuticals IncTrade
Dell Technologies IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Dell Technologies Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while Dell Technologies Inc trades at $468.46 (market cap $284.93B). The key difference: Dell Technologies Inc is far larger — about 14239.4× Citius Pharmaceuticals Inc's market cap, and Dell Technologies Inc pays a 0.57% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRDELL
Market Cap
$20.01M$284.93B
Sector
HealthTechnology
52-Week High
$1.82$467.27
52-Week Low
$0.48$111.10
Enterprise Value
$16.23M$304.51B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Dell Technologies Inc

Dell Technologies stock trades at $467.28, up 2.04% today, with strong bullish momentum driven by AI server demand and consistent earnings beats. The technical outlook is bullish with moving averages supporting upward trends, while fundamentals show revenue growth to $95.57B in 2025 and a net income margin of 6.28%. Analyst consensus is positive with a $503.76 price target, reflecting optimism around Dell's positioning in the AI infrastructure market.

The outlook for Dell remains favorable due to robust AI-driven server demand and solid financial performance, though risks include valuation concerns at a P/E of 35.14 and competitive pressures. Investors should weigh the growth potential against potential margin compression and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Dell Technologies Inc

VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses

Read more on DELL